Matrix metalloproteinase 9 (MMP-9) gene polymorphism and MMP-9 plasma levels in primary Sjogren's syndrome.

OBJECTIVES To determine whether plasma matrix metalloproteinase 9 (MMP-9) and MMP9 (-1562C-->T) polymorphism have an effect on the disease phenotype in primary Sjogren's syndrome (pSS). METHODS Plasma MMP-9 concentrations and polymorphism of the MMP9 gene were analysed in 66 patients with pSS. These data were studied in relation to the clinical data of the patients. The genetic data of patients were compared with the data of 66 healthy subjects. RESULTS Plasma MMP-9 was higher in patients with definite pSS than in patients with possible pSS. This association was principally caused by higher plasma MMP-9 in patients with a positive Schirmer test and keratoconjunctivitis sicca. pSS patients with purpura, SS-A autoantibodies and RF had significantly lower plasma MMP-9 than patients without these characteristics. The overall MMP9 (-1562C-->T) allele frequencies were similar in patients and control subjects. The frequency of the allele T was higher in patients without Raynaud's phenomenon than in the control group. CONCLUSIONS MMP9 (-1562C-->T) could not be used for risk assessment in pSS. The presence of the rarer allele T may decrease the risk of Raynaud's phenomenon in pSS. High plasma MMP-9 is indicative of definite pSS but may paradoxically have a preventive effect on the eruption of purpura and on the development of autoantibody reaction in pSS.

[1]  R. Fox,et al.  Sjögren's syndrome , 1995, The Lancet.

[2]  F. Ingegnoli,et al.  [Raynaud's phenomenon]. , 2011, Reumatismo.

[3]  P. E. Van den Steen,et al.  Cleavage of denatured natural collagen type II by neutrophil gelatinase B reveals enzyme specificity, post‐translational modifications in the substrate, and the formation of remnant epitopes in rheumatoid arthritis , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[4]  E. Mozes,et al.  Activity of matrix metalloproteinase‐9 is elevated in sera of patients with systemic lupus erythematosus , 2002, Clinical and experimental immunology.

[5]  Yunhee Lee,et al.  Matrix Metalloproteinase Gelatinase B (MMP-9) Coordinates and Effects Epithelial Regeneration* , 2002, The Journal of Biological Chemistry.

[6]  A. Solomon,et al.  Regulation of MMP-9 production by human corneal epithelial cells. , 2001, Experimental eye research.

[7]  A. Solomon,et al.  Pro- and anti-inflammatory forms of interleukin-1 in the tear fluid and conjunctiva of patients with dry-eye disease. , 2001, Investigative ophthalmology & visual science.

[8]  T. Lehtimäki,et al.  Coronary Artery Complicated Lesion Area Is Related to Functional Polymorphism of Matrix Metalloproteinase 9 Gene: An Autopsy Study , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[9]  Inge Nelissen,et al.  Gelatinase B functions as regulator and effector in leukocyte biology , 2001, Journal of leukocyte biology.

[10]  A. Pasternack,et al.  Elevated interleukin-6 plasma levels are regulated by the promoter region polymorphism of the IL6 gene in primary Sjögren's syndrome and correlate with the clinical manifestations of the disease. , 2001, Rheumatology.

[11]  S. Maxwell,et al.  Matrix metalloproteinase-1 and -9 activation by plasmin regulates a novel endothelial cell-mediated mechanism of collagen gel contraction and capillary tube regression in three-dimensional collagen matrices. , 2001, Journal of cell science.

[12]  K. Tokunaga,et al.  Comparison of statistical power between 2 * 2 allele frequency and allele positivity tables in case-control studies of complex disease genes. , 2001, Annals of human genetics.

[13]  R. Pinto,et al.  Differential expression of matrix metalloproteinases in labial salivary glands of patients with primary Sjögren's syndrome. , 2000, Arthritis and rheumatism.

[14]  K. Harada,et al.  Suppression of tumor necrosis factor alpha-induced matrix metalloproteinase 9 production by the introduction of a super-repressor form of inhibitor of nuclear factor kappaBalpha complementary DNA into immortalized human salivary gland acinar cells. Prevention of the destruction of the acinar structu , 2000, Arthritis and rheumatism.

[15]  A. Pasternack,et al.  The occurrence of renal involvement in primary Sjögren's syndrome: a study of 78 patients. , 1999, Rheumatology.

[16]  A. Evans,et al.  Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. , 1999, Circulation.

[17]  P. Koolwijk,et al.  A novel and simple immunocapture assay for determination of gelatinase-B (MMP-9) activities in biological fluids: saliva from patients with Sjögren's syndrome contain increased latent and active gelatinase-B levels. , 1998, Matrix biology : journal of the International Society for Matrix Biology.

[18]  A. Eisen,et al.  Matrix metalloproteinase (MMP)-9 type IV collagenase/gelatinase implicated in the pathogenesis of Sjögren's syndrome. , 1998, Matrix biology : journal of the International Society for Matrix Biology.

[19]  A. Koch,et al.  Expression of matrix metalloproteinase 9 (96-kd gelatinase B) in human rheumatoid arthritis. , 1996, Arthritis and rheumatism.

[20]  W. Stetler-Stevenson,et al.  Matrix metalloproteinases and tumor invasion: from correlation and causality to the clinic. , 1996, Seminars in cancer biology.

[21]  L Steinman,et al.  Multiple Sclerosis: A Coordinated Immunological Attack against Myelin in the Central Nervous System , 1996, Cell.

[22]  D. Isenberg,et al.  Preliminary criteria for the classification of Sjögren's syndrome. Results of a prospective concerted action supported by the European Community. , 1993, Arthritis and rheumatism.

[23]  Shirley A. Miller,et al.  A simple salting out procedure for extracting DNA from human nucleated cells. , 1988, Nucleic acids research.

[24]  C. Robinson,et al.  Sjögren's syndrome. Proposed criteria for classification. , 1986, Arthritis and rheumatism.

[25]  D. Chisholm,et al.  Labial salivary gland biopsy in Sjögren's disease , 1968, Journal of clinical pathology.